Improved post-thaw recovery of peripheral blood stem/progenitor cells using a novel intracellular-like cryopreservation solution
- 1 January 2009
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 11 (4) , 472-479
Abstract
Background aims Peripheral blood stem cells (PBSC) have become the preferred stem cell source for autologous hematopoietic transplantation. A critical aspect of this treatment modality is cryopreservation of the stem cell products, which permits temporal separation of the PBSC mobilization/collection phase from the subsequent high-dose therapy. While controlled rate-freezing and liquid nitrogen storage have become ‘routine’ practice in many cell-processing facilities, there is clearly room for improvement as current cryopreservation media formulations still result in significant loss and damage to the stem/progenitor cell populations essential for engraftment, and can also expose the patients to relatively undefined serum components and larger volumes of dimethylsulfoxide (DMSO) that can contribute to the morbidity and mortality of the transplant therapy. Methods This study compared cryopreservation of PBSC in a novel intracellular-like, fully defined, serum- and protein-free preservation solution, CryoStor™ (BioLife Solutions Inc.), with a standard formulation used by the Fred Hutchinson Cancer Research Center (FHCRC). Briefly, human PBSC apheresis specimens were collected and 5 × 10 7 cells/1 mL sample vial were prepared for cryopreservation in the following solutions: (a) FHCRC standard, Normosol-R, 5% human serum albumin (HAS) and 10% DMSO; and (b) CryoStor CS10 (final diluted concentration of 5% DMSO). A standard controlled-rate freezing program was employed, and frozen vials were stored in the vapor phase of a liquid nitrogen freezer for a minimum of 1 week. Vials were then thawed and evaluated for total nucleated cell count (TNC), viability, CD34 and granulocytes by flow cytometry, along with colony-forming activity in methylcellulose. Results The PBSC samples frozen in CryoStor CS10 yielded significantly improved post-thaw recoveries for total viable CD34 +, colony-forming units (CFU) and granulocytes. Specifically, relative to the FHCRC standard formulation, cryopreservation with CS10 resulted in an average 1.8-fold increased recovery of viable CD34 + cells ( P=0.005), a 1.5-fold increase in CFU-granulocyte–macrophage (GM) numbers ( P=0.030) and a 2.3-fold increase in granulocyte recovery ( P=0.045). Conclusions This study indicates that use of CryoStor for cryopreservation can yield significantly improved recovery and in vitro functionality of stem/progenitor cells in PBSC products. In addition, it is important to note that these improved recoveries were obtained while not introducing any extra serum or serum-derived proteins, and reducing the final concentration/volume of DMSO by half. Further in vitro and in vivo studies are clearly necessary; however, these findings imply use of CryoStor for cryopreservation could result in improved engraftment for those patients with a lower content of CD34 + cells in their PBSC collections, along with reducing the requirement for additional apheresis collections and decreasing the risk of adverse infusion reactions associated with higher exposure to DMSO.Keywords
This publication has 20 references indexed in Scilit:
- Cryopreservation of hematopoietic stem cellsAmerican Journal of Hematology, 2007
- Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environmentCurrent Opinion in Immunology, 2006
- Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantationBone Marrow Transplantation, 2006
- Has allogeneic stem cell cryopreservation been given the ‘cold shoulder’? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantationBone Marrow Transplantation, 2006
- Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte–colony‐stimulating factorTransfusion, 2005
- Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell productsBone Marrow Transplantation, 2005
- Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftmentBone Marrow Transplantation, 2005
- Mobilization and collection of peripheral blood progenitor cells for transplantationTransfusion and Apheresis Science, 2005
- A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarchBone Marrow Transplantation, 2003
- Peripheral Blood Progenitor Cell TransplantationTherapeutic Apheresis, 2002